GleamWall
中文EN

ALMS ALUMIS INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1847367 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-72.6%
TTM EPS YoY-64.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-6,116.7%
Net margin-5,844.5%
FCF margin-4,433.3%
EBITDA margin-6,069.2%

Returns

ROE-110.9%
ROA-86.6%
ROIC (approx.)-109.3%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets22.6%
Debt / equity0.00x
Current ratio5.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-21.1%
Payout ratio—
Capex / revenue11.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$24.05M—
R&D expense$386.00M$265.55M
SG&A expense$91.86M$35.20M
Operating income-$453.80M-$300.75M
Pretax income-$251.89M-$294.23M
Income tax-$8.56M$0
Net income-$243.32M-$294.23M
EBITDA-$450.31M-$297.60M
EPS (basic)-2.86-10.38
EPS (diluted)-2.86-10.38
Weighted avg. shares (diluted)85.03M28.34M
Balance sheet
Cash & equivalents$89.67M$170.63M
Short-term investments$218.83M$118.74M
Current assets$318.23M$306.19M
PP&E, net$18.19M$20.97M
Total assets$411.94M$340.99M
Current liabilities$73.32M$50.91M
Total liabilities$110.64M$80.89M
Shareholders' equity$301.30M$260.10M
Cash flow statement
Operating cash flow-$369.52M-$255.08M
Capital expenditure$653,000$1.73M
Free cash flow-$370.18M-$256.81M
Investing cash flow$287.88M-$113.79M
Financing cash flow$2.07M$492.37M
Depreciation & amortization$3.50M$3.15M
Stock-based compensation$43.52M$19.46M
Share buybacks$17,000$6,000

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.